Carecubes, a healthcare solutions company focused on preventing infectious disease transmission, announced it has raised $6.5 million in a Series A funding round backed by prominent healthcare and public sector leaders. The funding marks a significant milestone as the company scales deployment of its FDA 510(k)-cleared isolation unit designed for rapid use across healthcare settings.
The company’s flagship product, the Carecube, reimagines traditional infection control by isolating the pathogen rather than the patient. This approach allows healthcare providers to deliver safer and more compassionate care while reducing reliance on personal protective equipment and minimizing strain on hospital infrastructure.
Carecubes has already seen adoption across more than 36 communities spanning 13 states and territories. Early customers include major hospitals, public health departments, and emergency response systems, reflecting growing demand for scalable infection control solutions.
The company is led by CEO Alex Laskey, founder of Opower, and co-founder Saul Griffith, a MacArthur Fellow and founder of Otherlab. The Series A drew support from high-profile investors and operators across healthcare, including leadership from Oscar Health, Aetna, Medtronic, and Cardinal Health, along with institutional investors such as Schooner Capital, Lifeforce Capital, and CQuence Health.
The Carecube technology was initially funded by DARPA and further supported by the CDC and the Administration for Strategic Preparedness and Response. It was developed in collaboration with infectious disease experts at the University of Nebraska Medical Center.
Manufactured in Minnesota with supply chain partners across several U.S. states, the Carecube is designed for rapid deployment in hospitals and emergency settings. The system enables bedside care while protecting healthcare workers and patients, improving throughput, reducing waste, and expanding isolation capacity without requiring specialized infrastructure.
Carecubes is addressing persistent gaps in healthcare preparedness, particularly in managing airborne infectious diseases such as measles, RSV, and tuberculosis. The company aims to provide an affordable and scalable solution that can help prevent small outbreaks from escalating into larger public health crises.
KEY QUOTES:
“We started Carecubes to solve a long-standing failure in healthcare: the idea that we must choose between protecting providers and delivering quality care to patients. With the close of our Series A and the extraordinary support from our partners and investors, we’re proving that it’s possible to do both, safely, compassionately, and at scale.”
Alex Laskey, CEO of Carecubes
“Carecubes can help prevent small outbreaks from becoming large ones, and its development is a testament to what’s possible when public universities and private partners work together.”
Dr. Dele Davies, Interim Chancellor of the University of Nebraska Medical Center
“Carecubes is exactly the kind of high-impact innovation our healthcare system needs, delivering an affordable, scalable technology to strengthen infectious disease response and protect patients. I’m proud to invest in Carecubes and work with its exceptional team and partners on this critical work.”
Mark Bertolini, CEO of Oscar Health and Former CEO of Aetna
“With the Carecube, a family member can look through the clear walls, touch their loved one through a protective sleeve, and know they are still present. That simple act of connection matters everywhere, whether in the Democratic Republic of Congo, rural Nebraska, or New York City.”
Henrietta Fore, Former Executive Director of UNICEF and Former Administrator of USAID
“Carecubes stands out because it is unique, it meets an urgent need, and it improves both provider safety and patient experience. From my perspective as someone who ran one of the largest healthcare supply chain companies in the world, what excites me most is the Carecubes’ potential for scale.”
Mike Kaufmann, Former CEO of Cardinal Health
